Table 2. Characteristics of included patients.
| Study ID | Participants(n): TPO-RA vs Control | Gender: Female/Male(n): TPO-RA vs Control | Age(years): TPO-RA vs Control | Duration of ITP(years): TPO-RA vs Control | Splenectomy status(yes/no)(n): TPO-RA vs Control | Baseline platelet count(109/L): TPO-RA vs Control | Concomitant ITP medication: TPO-RA vs Control |
|---|---|---|---|---|---|---|---|
| Bussel 2007 [16] | 88(ELT) vs 29(PLA) | 57/31 vs 16/13 | 51(23–79);45(23–81);55(18–85) vs 42(18–85) | >0.5 vs >0.5 | 41/47 vs 14/15 | PC ≤15×109/L: 42/88 vs 14/29 | 32/88 vs 6/29 |
| Bussel 2009 [17] | 76(ELT) vs 38(PLA) | 43/33 vs 27/11 | 47(19–84) vs 51(21–79) 51±17 vs 48±16 | >0.5 vs >0.5 | 31/45 vs 14/24 | PC ≤15×109/L: 38/76 vs 17/38 | 32/76 vs 17/38 |
| Cheng 2011 [18] | 135(ELT) vs 62(PLA) | 93/42 vs 43/19 | 47.0(34–56) vs 52.5(43–63) | >0.5 vs >0.5 | 50/85 vs 21/41 | 16(8–22) vs 16(9–24) PC ≤15×109/L: 67/135 vs 30/62 | 63/135 vs 31/62 |
| Tomiyama 2012 [19] | 15(ELT) vs 8(PLA) | 8/7 vs 7/1 | 58.0(26–72) vs 60.5(38–72) | >0.5 vs >0.5 | 11/4 vs 5/3 | 21(16–25) vs 9.5(7.5–19) PC ≤15×109/L: 3/15 vs 6/8 |
12/15 vs 7/8 |
| Yang 2017 [20] | 104(ELT) vs 51(PLA) | 77/27 vs 40/11 | 48(18–84) vs 42(22–66) 44.7 ±15.91 vs 41.3±12.83 | >1.0 vs >1.0 | 18/86 vs 7/44 | 14.0 vs 13.5 PC ≤15×109/L: 54/104 vs 28/51 | 53/104 vs 28/51 |
| Bussel 2006 [21] | 17(ROM) vs 4(PLA) | 12/5 vs 3/1 | 45(20–63);53(19–62);42 vs 55(39–64) | 5.6(0.5–24.9);9.1(0.4–37.0); 6.4 vs 3.4(0.8–3.7) | 13/4 vs 1/3 | 17(4–25);12(5–23);15 vs 29(6–49) | 4/17 vs 3/4 |
| Kuter 2008a [22] | 42(ROM) vs 21(PLA) | 27/15 vs 11/10 | 51(27–88) vs 56(26–72) | 7.8(0.6–44.8) vs 8.5(1.1–31.4) | 42/0 vs 21/0 | 14(3–29) vs 15(2–28) | 12/42 vs 6/21 |
| Kuter 2008b [22] | 41(ROM) vs 21(PLA) | 27/14 vs 16/5 | 52(21–80) vs 46(23–88) | 2.2(0.1–31.6) vs 1.6(0.1–16.2) | 0/41 vs 0/21 | 19(2–29) vs 19(5–31) | 11/41 vs 10/21 |
| Shirasugi 2011 [23] | 22(ROM) vs 12(PLA) | 14/8 vs 10/2 | 58.5±12.6 vs 47.6±13.4 | 9.7±10.4 vs 7.6±5.9 | 10/12 vs 5/7 | 18.4±8.3 vs 15.8±6 | 13/22 vs 10/12 |
PC: Platelet count; ELT: Eltrombopag; ROM: Romiplostim; PLA: Placebo.